35 results
8-K
EX-99.1
LYEL
Lyell Immunopharma, Inc.
7 Nov 23
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023
4:08pm
and uncertainties related to: the effects of geopolitical instability; macroeconomic conditions and the lingering effects of the COVID-19 pandemic; Lyell’s
8-K
EX-99.1
LYEL
Lyell Immunopharma, Inc.
11 Sep 23
Regulation FD Disclosure
9:16am
to: the effects of geopolitical instability; macroeconomic conditions and the lingering effects of the COVID-19 pandemic; our ability to submit planned INDs
8-K
EX-99.1
d9ua xdiutg6s
8 Aug 23
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023
4:10pm
8-K
EX-99.1
sqxa36iud2f4 s321
4 May 23
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2023
4:11pm
8-K
EX-99.1
on8ts7 k0mid
16 Dec 22
Lyell Immunopharma Appoints Lynn Seely, MD as President and Chief Executive Officer
4:02pm
8-K
EX-99.1
ywbg32 63
8 Nov 22
Lyell Immunopharma Reports Recent Business Highlights and Third Quarter Financial Results
4:07pm
8-K
syphs 6wqtoi
24 Oct 22
Termination of a Material Definitive Agreement
5:20pm
8-K
EX-99.1
sflw4s2i3ep0 p3
6 Oct 22
Regulation FD Disclosure
4:37pm
S-3ASR
xdq96sd7b a8hhz0p
4 Aug 22
Automatic shelf registration
5:29pm
8-K
EX-99.1
hv9t5bpv
4 Aug 22
Lyell Immunopharma Reports Second Quarter Financial Results and Business Highlights
4:16pm
8-K
EX-99.1
u9m owxysfc
10 May 22
Lyell Immunopharma Reports First Quarter Financial Results and Business Highlights
4:14pm
DEF 14A
n72jkk
28 Apr 22
Definitive proxy
4:11pm